Preston Klassen Sells 380,605 Shares of Metacrine, Inc. (NASDAQ:MTCR) Stock
Preston Klassen Sells 380,605 Shares of Metacrine, Inc. (NASDAQ:MTCR) Stock
Metacrine, Inc. (NASDAQ:MTCR – Get Rating) CEO Preston Klassen sold 380,605 shares of the firm's stock in a transaction on Thursday, January 26th. The stock was sold at an average price of $0.41, for a total value of $156,048.05. Following the completion of the transaction, the chief executive officer now owns 541,905 shares of the company's stock, valued at approximately $222,181.05. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Metacrine, Inc.（纳斯达克股票代码：MTCR — 获取评级）首席执行官普雷斯顿·克拉森在1月26日星期四的一笔交易中出售了该公司380,605股股票。该股的平均售价为0.41美元，总价值为156,048.05美元。交易完成后，首席执行官现在拥有该公司541,905股股票，价值约为222,181.05美元。此次出售是在向美国证券交易委员会提交的文件中披露的，该文件可通过以下方式获得 这个超链接。
Metacrine Stock Performance
Metacrine 股票表现
NASDAQ MTCR opened at $0.48 on Friday. The stock has a 50-day simple moving average of $0.43 and a two-hundred day simple moving average of $0.45. The firm has a market capitalization of $20.44 million, a P/E ratio of -0.47 and a beta of -0.92. Metacrine, Inc. has a fifty-two week low of $0.30 and a fifty-two week high of $0.68. The company has a debt-to-equity ratio of 0.34, a quick ratio of 12.15 and a current ratio of 12.15.
纳斯达克MTCR周五开盘价为0.48美元。该股的50天简单移动平均线为0.43美元，两百天简单移动平均线为0.45美元。该公司的市值为2044万美元，市盈率为-0.47，beta值为-0.92。Metacrine, Inc.创下五十二周低点0.30美元，五十二周高点为0.68美元。该公司的债务与权益比率为0.34，速动比率为12.15，流动比率为12.15。
Metacrine (NASDAQ:MTCR – Get Rating) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). On average, equities analysts forecast that Metacrine, Inc. will post -0.62 earnings per share for the current year.
Metacrine（纳斯达克股票代码：MTCR — Get Rating）上次发布季度收益数据是在11月14日星期一。该公司公布了本季度每股收益（0.13美元），比分析师普遍预期的（0.11美元）低了（0.02美元）。股票分析师平均预测，Metacrine, Inc.本年度的每股收益将为-0.62。
Hedge Funds Weigh In On Metacrine
对冲基金权衡美塔克林
Analysts Set New Price Targets
分析师设定了新的价格目标
Separately, HC Wainwright restated a "neutral" rating on shares of Metacrine in a research note on Wednesday, November 16th.
另外，HC Wainwright在11月16日星期三的一份研究报告中重申了对Metacrine股票的 “中性” 评级。
About Metacrine
关于 Metacrine
(Get Rating)
（获取评分）
Metacrine, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc was incorporated in 2014 and is headquartered in San Diego, California.
Metacrine, Inc是一家临床阶段的生物制药公司，专注于为胃肠道疾病患者发现和开发疗法。它正在开发 MET642，该试验已完成治疗溃疡性结肠炎的 I 期临床试验。Metacrine, Inc成立于2014年，总部位于加利福尼亚州圣地亚哥。
Featured Articles
精选文章
- Get a free copy of the StockNews.com research report on Metacrine (MTCR)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免费获取 StockNews.com 关于 Metacrine (MTCR) 的研究报告
- MarketBeat Week 回顾 — 1/23-1/27
- 为什么 Lucid 在一天之内飙升了近 100%
- 利用这些铁路股票实现增长和收入
- ASML 预计今年对芯片的需求将上涨，提振了销售前景
- KLA 公司：在陷入困境的半市场中的实力
Receive News & Ratings for Metacrine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metacrine and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Metacrine Daily 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Metacrine及相关公司的最新新闻和分析师评级的简明每日摘要。